Title:
The therapeutic antigen joint molecule which has a FcRn connection domain which promotes antigen clearance
Document Type and Number:
Japanese Patent JP6204350
Kind Code:
B2
Abstract:
The present invention provides: a modified FcRn-binding domain having an enhanced affinity for the Fc Receptor neonatal (FcRn) at neutral pH; an antigen-binding molecule comprising said FcRn-binding domain, which has low immunogenicity, high stability and form only a few aggregates; a modified antigen-binding molecule having an increased FcRn-binding activity at neutral or acidic pH without an increased binding activity at neutral pH for a pre-existing anti-drug antibody; use of the antigen-binding molecules for improving antigen-binding molecule-mediated antigen uptake into cells; use of the antigen-binding molecules for reducing the plasma concentration of a specific antigen; use of the modified FcRn-binding domain for increasing the total number of antigens to which a single antigen-binding molecule can bind before its degradation; use of the modified FcRn-binding domain for improving pharmacokinetics of an antigen-binding molecule; methods for decreasing the binding activity for a pre-existing anti-drug antibody; and methods for producing said antigen-binding molecules.
More Like This:
Inventors:
Tomoyuki Ikawa
Atsuhiko Maeda
Ajmoto Futa
Taichi Kuramochi
Atsuhiko Maeda
Ajmoto Futa
Taichi Kuramochi
Application Number:
JP2014514947A
Publication Date:
September 27, 2017
Filing Date:
September 28, 2012
Export Citation:
Assignee:
Chugai Pharmaceutical Co., Ltd.
International Classes:
C07K16/28; A61K39/395
Domestic Patent References:
| JP2008519860A | ||||
| JP2003512019A |
Foreign References:
| WO2010106180A1 |
Other References:
DALL'ACQUA, W.F. et al.,"Increasing the affinity of a human IgG1 for the neonatal Fc receptor: Biological consequences.",J. IMMUNOL.,2002年11月 1日,Vol.169, No.9,pp.5171-5180
VACCARO, C. et al.,"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.",NATURE BIOTECHNOLOGY,2005年10月,Vol.23, No.10,pp.1283-1288
ARAUJO, J. et al.,"Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody.",JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,2011年 7月15日,Vol.55, No.5,pp.1041-1049
ZHENG, Y. et al.,"Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.",CLINICAL PHARMACOLOGY AND THERAPEUTICS,2011年 2月,Vol.89, No.2,pp.283-290,(EPUB 2010 DEC 29)
VACCARO, C. et al.,"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.",NATURE BIOTECHNOLOGY,2005年10月,Vol.23, No.10,pp.1283-1288
ARAUJO, J. et al.,"Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody.",JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,2011年 7月15日,Vol.55, No.5,pp.1041-1049
ZHENG, Y. et al.,"Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.",CLINICAL PHARMACOLOGY AND THERAPEUTICS,2011年 2月,Vol.89, No.2,pp.283-290,(EPUB 2010 DEC 29)
Attorney, Agent or Firm:
Hatsushi Shimizu
Masao Haruna
Hirotaka Yamaguchi
Toshi Gobe
Ryuichi Inoue
Toshimitsu Sato
Koichi Niimi
Tomohiko Kobayashi
Masato Ozeki
Yoshihiro Igarashi
Kazuya Kawamoto
Masao Haruna
Hirotaka Yamaguchi
Toshi Gobe
Ryuichi Inoue
Toshimitsu Sato
Koichi Niimi
Tomohiko Kobayashi
Masato Ozeki
Yoshihiro Igarashi
Kazuya Kawamoto
Previous Patent: The constituent for injectable solutions
Next Patent: PACKAGE ASSEMBLY OF SURFACE MOUNTING TYPE ELECTRONIC PART
Next Patent: PACKAGE ASSEMBLY OF SURFACE MOUNTING TYPE ELECTRONIC PART